Fluid Biopsy Market Size (2024 - 2029)

The fluid biopsy market is projected to experience significant growth over the forecast period, driven by the increasing demand for non-invasive diagnostic procedures and the rising incidence of cancer globally. The market's expansion is further supported by advancements in liquid biopsy technologies, which have gained prominence due to their application in diagnosing conditions like COVID-19. Despite the positive growth trajectory, the market may face challenges from the emerging popularity of alternative diagnostic technologies such as optical biopsies.

Market Size of Fluid Biopsy Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Fluid Biopsy Market Summary
Study Period 2021 - 2029
Market Size (2024) USD 6.11 Billion
Market Size (2029) USD 13.05 Billion
CAGR (2024 - 2029) 16.40 %
Fastest Growing Market Asia-Pacific
Largest Market North America

Major Players

Fluid Biopsy Market Major Players

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Fluid Biopsy Market Analysis

The Fluid Biopsy Market size is estimated at USD 6.11 billion in 2024, and is expected to reach USD 13.05 billion by 2029, growing at a CAGR of 16.40% during the forecast period (2024-2029).

COVID-19 had a significant impact on the fluid biopsy market during the pandemic period. The increasing developments of fluid biopsy in the diagnosis of COVID-19 are expected to contribute to the growth of the market. For instance, the article published in the JAMA network in March 2021 mentioned that researchers at Cornell University developed a "liquid biopsy" that detected and quantified injury to internal organs from the COVID-19 virus. This liquid biopsy test profiled epigenetic changes in circulating cell-free DNA-small fragments of genetic material from dead cells, including those killed off by infection or immune-related injury. Thus, such developments in liquid biopsy for the COVID-19 infection had a notable impact on the growth of the market during the pandemic period. Also, the demand for fluid biopsy is expected to remain intact during the post-pandemic period due to the increasing focus on various chronic and infectious diseases, thereby contributing to the growth of the market over the forecast period.

The market is expected to grow because there are more cases of cancer around the world and more people want non-invasive diagnostic procedures.

As per the World Health Organization fact sheet published in February 2022, in 2021, there were an estimated 1.9 million new cancer cases diagnosed in the United States. The report also mentioned that each year, approximately 400,000 children worldwide develop cancer estimated 1.9 million new cancer cases diagnosed in the United States. The report also mentioned that each year, approximately 400,000 children worldwide develop cancer. Cervical cancer is the most common in 23 countries, such as Eswatini, India, South Africa, Latin America, and others. The most common cancers are breast, lung, colon, rectum, and prostate cancers. Thus, the higher cases of cancer are generating demand for fluid biopsy due to its non-invasive diagnostic procedure, thereby contributing to the growth of the market.

Also, the market players' initiatives, such as partnerships, mergers, product launches, and product developments, are expected to boost the growth of the market. For instance, in December 2021, Epic Sciences Inc. launched DefineMBC, a novel metastatic breast cancer (MBC) test that includes both cell-based and cell-free analysis from a single blood draw. Define MBC provides comprehensive MBC profiling when a tissue biopsy result is not available. Additionally, in March 2021, Sysmex Europe GmbH, in partnership with Sysmex Inostics GmbH, launched Plasma-SeqSensei liquid biopsy Research Use Only (RUO) kits for colorectal cancer, non-small cell lung cancer, melanoma, and thyroid cancer.

Thus, the rising cases of cancer across the world and innovative product developments are expected to contribute to the growth of the market. Over the next few years, however, the growth of the market is likely to be slowed by the growing popularity of alternative technologies like optical biopsies.

Fluid Biopsy Industry Segmentation

As per the scope of the report, fluid biopsy, also known as liquid biopsy or fluid phase biopsy, is a procedure of sampling and analyzing non-solid biological tissues (blood and others) for the screening of cancer and other inflammatory conditions associated with cardiac and other medical disorders. The Fluid Biopsy Market is segmented by Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, and Other Indications), Type (Circulating Tumor Cells, Circulating Tumor DNA, and Cell-free DNA), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Indication
Lung Cancer
Breast Cancer
Colorectal
Other Indications
By Type
Circulating Tumor Cells
Circulating Tumor DNA
Cell-free DNA
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Fluid Biopsy Market Size Summary

The fluid biopsy market is poised for significant growth over the forecast period, driven by the increasing prevalence of cancer and the rising demand for non-invasive diagnostic procedures. The market's expansion is further supported by advancements in fluid biopsy technologies, which have gained prominence during the COVID-19 pandemic. These technologies have been instrumental in diagnosing COVID-19-related organ injuries, thereby enhancing their visibility and application in the medical field. The ongoing focus on chronic and infectious diseases continues to sustain the demand for fluid biopsies, positioning the market for robust growth. Additionally, strategic initiatives by key market players, including partnerships, mergers, and innovative product launches, are expected to further propel market development.

North America is anticipated to lead the fluid biopsy market, bolstered by a high incidence of cancer and substantial research and development activities in the region. The presence of major market players and frequent product innovations contribute to this dominance. The market's competitive landscape is characterized by a few key players, such as Bio-Rad Laboratories, Guardant Health, and Qiagen, who currently hold significant market shares. Despite the promising growth trajectory, the market faces challenges from alternative technologies like optical biopsies. However, the continuous development of non-invasive diagnostic solutions, particularly for breast cancer, is expected to drive segment growth and maintain the market's upward momentum.

Explore More

Fluid Biopsy Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rising Demand for Non-invasive Diagnostic Procedures

      2. 1.2.2 Increasing Number of Cancer Cases Worldwide

    3. 1.3 Market Restraints

      1. 1.3.1 Increasing Preference For Alternative Technologies like Optical Biopsies

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Indication

      1. 2.1.1 Lung Cancer

      2. 2.1.2 Breast Cancer

      3. 2.1.3 Colorectal

      4. 2.1.4 Other Indications

    2. 2.2 By Type

      1. 2.2.1 Circulating Tumor Cells

      2. 2.2.2 Circulating Tumor DNA

      3. 2.2.3 Cell-free DNA

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Fluid Biopsy Market Size FAQs

The Fluid Biopsy Market size is expected to reach USD 6.11 billion in 2024 and grow at a CAGR of 16.40% to reach USD 13.05 billion by 2029.

In 2024, the Fluid Biopsy Market size is expected to reach USD 6.11 billion.

Fluid Biopsy Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)